Genprex enters patent license agreement with NYU Langone Health

Genprex ( NASDAQ: GNPX ) said it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa Gene Therapy. The firm added that the therapy is under investigation as a potential treatment for mesothelioma. The subject patent is co-owned by Genprex and NYU Langone Health, and the license provides Genprex with patent exclusivity.

More on Genprex Seeking Alpha’s Quant Rating on Genprex Financial information for Genprex.